Hepatitis B
Most Hepatitis B Patients Who Respond to Tenofovir Show Improved Liver Health at 5 Years
- Details
- Category: HBV Treatment
- Published on Thursday, 27 December 2012 00:00
- Written by Liz Highleyman
Treatment with tenofovir (Viread) remains safe and effective over 5 years, and people who achieve sustained viral load suppression experience improvement in liver histology, including regression of fibrosis and cirrhosis, according to study findings described in the December 7, 2012, advance online edition of The Lancet.
FDA Committee Says Heplisav Hepatitis B Vaccine Is Effective, but Safety Data Inadequate
- Details
- Category: HBV Vaccines
- Published on Friday, 21 December 2012 00:00
- Written by Dynavax
A U.S. Food and Drug Administration (FDA) committee last month concurred that Dynavax's investigational hepatitis B virus (HBV) vaccine Heplisav was effective in preventing infection, but a majority thought there was not enough data to show whether the vaccine is safe.
FDA: Do Not Mix Hepatitis B Drug Adefovir with Stribild HIV Combo Pill
- Details
- Category: Drug Advisories & Warnings
- Published on Tuesday, 04 December 2012 00:00
- Written by FDA
The U.S. Food and Drug Administration (FDA) last week announced an update to the label information for adefovir dipivoxil (Hepsera), adding the 4-in-1 antiretroviral combination pill Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) to the list of other products that should not be co-administered with adefovir.
AASLD 2012: Entecavir Shows Good Efficacy for Black and Hispanic Hepatitis B Patients
- Details
- Category: HBV Treatment
- Published on Tuesday, 18 December 2012 00:00
- Written by Liz Highleyman
The nucleoside analog entecavir (Baraclude) worked as well for previously untreated African-American and Hispanic/Latino hepatitis B patients as it did for the majority white and Asian study populations in prior clinical trials, according to a poster presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last month in Boston.
AASLD 2012: Brivanib Fails to Match Sorafenib for Liver Cancer, but Tivatinib Looks Promising
- Details
- Category: Liver Cancer/HCC
- Published on Friday, 30 November 2012 00:00
- Written by Liz Highleyman
The investigational cancer drug brivanib did not significantly increase overall survival for patients with hepatocellular carcinoma compared with existing standard therapy, researchers reported at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012) this month in Boston. But another drug, tivatinib, did appear beneficial for a subset of patients. 
AASLD 2012: Adding Pegylated Interferon to Entecavir Improves HBV Treatment Response
- Details
- Category: HBV Treatment
- Published on Tuesday, 11 December 2012 00:00
- Written by Liz Highleyman
Intensifying entecavir (Baraclude) treatment for hepatitis B by adding pegylated interferon lowers HBV viral load and increases the likelihood of hepatitis B "e" antigen (HBeAg) loss, according to a report at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last month in Boston. A related study found that hepatitis B surface antigen (HBsAg) levels during treatment can be used to predict response to interferon. 
AASLD 2012: When Are HCV Direct-Acting Antivirals Needed, Who Should Be Prioritized?
- Details
- Category: Liver Cancer/HCC
- Published on Monday, 26 November 2012 00:00
- Written by Rob Camp
When resources for hepatitis C treatment with new direct-acting antivirals are limited, findings from the U.S. suggest that previously untreated people with low HCV viral loads may stand a good chance of achieving sustained virological response without adding telaprevir or boceprevir to pegylated interferon and ribavirin, researchers reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this month in Boston. A related study suggests that younger hepatitis C patients with advanced liver disease should be prioritized for treatment with the new drugs.
AASLD 2012: Patients with Cirrhosis Can Respond Well to Boceprevir or Telaprevir with Careful Monitoring
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 04 December 2012 00:00
- Written by Liz Highleyman
Real-world experience in the French early-access CUPIC study shows that hepatitis C patients with advanced liver damage can achieve good response to interferon-based triple-therapy including boceprevir (Victrelis) or telaprevir (Incivek), although adverse events are common, according to a presentation at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last month in Boston.
AASLD 2012: Nucleoside Analogs Reduce Hepatitis B Liver Cancer Risk, Cirrhosis Remains a Concern
- Details
- Category: HBV Treatment
- Published on Sunday, 25 November 2012 00:00
- Written by Liz Highleyman
Treatment of chronic hepatitis B with nucleoside/nucleotide analogs including lamivudine (Epivir-HBV) and entecavir (Baraclude) can reduce the risk of developing hepatocellular carcinoma, including cancer recurrence after successful resection, according to studies presented at the recent American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) and published in the Journal of the American Medical Association.
More Articles...
- AASLD 2012: Tenofovir Safe and Effective for Long-term Hepatitis B Treatment with Little Bone Loss
- Coverage of the 2012 AASLD Liver Meeting
- Liver Meeting Highlights: New Hep C Drugs, NAFLD, Liver Cancer, Acetaminophen Toxicity, Benefits of Coffee
- AASLD Liver Meeting Starts this Weekend in Boston
- Antiviral Therapy Safe and Effective for Hep B Patients with Advanced Cirrhosis
Web Design and Development by